The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
Li-Tzong Chen
Consultant or Advisory Role - PharmaEngine (U)
Her-Shyong Shiah
No relevant relationships to disclose
Peng-Chan Lin
No relevant relationships to disclose
Jenq-Chang Lee
No relevant relationships to disclose
Wu-Chou Su
No relevant relationships to disclose
Yi-Wen Wang
Employment or Leadership Position - PharmaEngine
Stock Ownership - PharmaEngine
Grace Yeh
Employment or Leadership Position - PharmaEngine
Stock Ownership - PharmaEngine
Jang-Yang Chang
No relevant relationships to disclose